Robert Ross, MD
Robert Ross, MD, oversees all clinical and regulatory operations and development efforts at Surface Oncology and is responsible for the advancement of Surface Oncology’s programs into the clinic.
Rob has extensive clinical development experience. Most recently he was at bluebird bio, leading the clinical development of genetically modified cellular therapies in thalassemia and sickle cell disease. Rob was also the head of oncology at bluebird bio, building a multifaceted oncology program, led by an anti-BCMA chimeric antigen T cell therapy in collaboration with Celgene. Previously, he worked at Genentech and Infinity Pharmaceuticals on both small molecule and antibody programs from Phase 1 through pivotal trials and also was a faculty member at the Dana Farber Cancer Center, treating patients with genitourinary malignancies.
Rob earned his BS from Stanford University his MS from Harvard Medical School and MD from Columbia University College of Physicians and Surgeons. He did his residency in Internal Medicine at the University of California, San Francisco and his fellowship in hematology/oncology at the combined program at the Dana Farber/Massachusetts General Hospital.